Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis — AI Research | MarketCI

ARWR

Market Closed

Arrowhead Pharmaceuticals, Inc.

NASDAQHealthcare Biotechnology

711 employees

CEO: Christopher R. Anzalone

Founded: 1993

$85.60

+$0.00(+NaN%)

Market Cap

12.06B

Beta

1.26

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

ARWR Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for ARWR built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Strong Sell

Pass %

42.86%

Score

3/7

Fair Value Estimate

Cash flow analysis • Multiple methods

-$98.24

AI Price Target

Machine learning • Price prediction

$80.93

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$0.00

Financial Health

Bankruptcy risk assessment

3.37

Quality Score

Financial strength rating

3.00

AI Investment Grade

Deep analysis of filings & news

65.00

Key Investment Highlights

Important factors affecting ARWR investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

63.89% Good

Conditions Met

23.00/36.00

Due Diligence Score

63.89%

Due Diligence Conditions

Investment analysis conditions and results


	Fail
	Pass
	Pass
	Pass
	Pass
	Pass

Showing 1 to 6 of 46 conditions